Shenzhen Zhongge Biotechnology Co. Ltd. has patented new translation initiation factor 2B (eIF2B) activators described as potentially useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, autoimmune, eye, renal and dermatological disorders, among others.

Guangzhou Lianrui Pharmaceutical Co. Ltd. has identified benzo bicyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists and reported to be useful for the treatment of diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity.

Shanghai Huilun Pharmaceutical Co. Ltd. has patented proteolysis targeting chimeric compounds (PROTACs) comprising E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1)-binding moiety through a linker.

China State Institute of Pharmaceutical Industry and Jiangsu Nhwa Pharmaceutical Co. Ltd. have jointly described aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivatives acting as serotonin 5-HT1A and/or dopamine D2 and/or D3 receptor agonists reported to be useful for the treatment of Parkinson’s disease.

Work at Remynd NV has led to the synthesis of (aza)spiroheptane derivatives potentially useful for the treatment of Alzheimer’s disease.

Nuvalent Inc. has disclosed new heteroaromatic macrocyclic ether compounds acting as proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.

Bristol Myers Squibb Co. has identified tetrazole derivatives acting as diacylglycerol kinase α (DGK-α; DGKA) and/or diacylglycerol kinase ζ (DGK-ζ; DGKZ) inhibitors reported to be useful for the treatment of cancer and viral infections.

Suzhou Lexbio Pharm Co. Ltd. has patented macrocyclic triazole derivatives acting as high-affinity nerve growth factor receptor (NTRK1; TRKA) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, neuropathic pain, Alzheimer’s and Parkinson’s diseases.